Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis

Journal of Dermatological Treatment

Volumn 27, Issue 3, 2016, Pages 241-246

  Ohba, Fuminori ^a   Nomoto, Maiko ^a   Hojo, Seiichiro ^a   Akama, Hideto ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Atopic eczema; clinical trial; patch test; phosphodiesterase 4 inhibitor; photopatch test; topical treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; E 6005; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; METHYL 4-(((3-(6,7-DIMETHOXY-2-(METHYLAMINO)QUINAZOLIN-4-YL)PHENYL)AMINO)CARBONYL)BENZOATE; OINTMENT; PHOSPHODIESTERASE IV INHIBITOR; PHTHALIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PHOTOPATCH TEST; PHOTOSENSITIVITY; PHOTOSENSITIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN IRRITATION; URTICARIA; AGED; DERMATITIS, ATOPIC; DOUBLE BLIND PROCEDURE; METABOLISM; MIDDLE AGED; NORMAL HUMAN; OINTMENT; TOPICAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, TOPICAL; ADULT; AGED; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PHOSPHODIESTERASE 4 INHIBITORS; PHTHALIC ACIDS; QUINAZOLINES; YOUNG ADULT;

EID: 84961205025     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2015.1093587     Document Type: Article

References (19)

1. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report. Allergy. 2006; 61: 969-87
2. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2013; 67: 1475-82
3. Parker CW, Kennedy S, Eisen AZ. Leukocyte and lymphocyte cyclic AMP responses in atopic eczema. J Invest Dermatol. 1977; 68: 302-6
4. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-Agonist hyporesponsiveness. J Allergy Clin Immunol. 1982; 70: 452-7
5. Chan SC, Reifsnyder D, Beavo JA, Hanifin JM. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol. 1993; 91: 1179-88
6. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Allergy Clin Immunol. 1995; 105 (Suppl): 84S-88S
7. Calverley PMA, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 176: 154-61
8. Papp KA, Kaufmann R, Thaçhi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013; 27: e376-83
9. Galvaldá A, Roberts RS. Phosphodiesterase-4 inhibitors: a review of current developments (2010-2012). Expert Opin Ther Patents. 2013; 23: 997-1016
10. Pagés L, Gavaldá A, Lehner MD. PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin Ther Patents. 2009; 19: 1501-19
11. Ishii N, Shirato M, Wakita H, et al. Anti-pruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013; 346: 105-12
12. Furue M, Kitahara Y, Akama H, et al. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014; 41: 577-85
13. Saeki H, Furue M, Furukawa F, et al. Guidelines for management of atopic dermatitis. J Dermatol. 2009; 36: 563-77
14. Wahlberg JE, Lindberg M. Patch testing. In Frosch PJ, Menne T, Lepoittevin JP., eds. Contact Dermatitis. 4th ed. Berlin: Springer, 2006. p 366-90
15. Irie S, Tsukikawa H, Nabeshima T, et al. Skin tests of a novel nicotine patch, PHK-301p, in healthy male volunteers: phase I, placebo-controlled study. J Pharmacol Sci. 2006; 102: 72-6
16. Palmer RA, White IR. Photopatch testing. In Frosch PJ, Menne T, Lepoittevin JP., eds. Contact Dermatitis. 4th ed. Berlin: Springer, 2006 p 433-40
17. Nakagawa H. Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis. Clin Drug Invest. 2006; 26: 235-46
18. Robichaud A, Stamatiou PB, Jin SLC, et al. Deletion of phosphodiesterase 4D in mice shortens 2-Adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002; 110: 1045-52
19. Robichaud A, Tattersall FD, Choudhury I, et al. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology. 1999; 38: 289-97